Circulating tumor DNA analysis of metastatic renal cell carcinoma.
The genomic landscape of metastatic renal cell carcinoma (RCC) is not well understood, and currently available data suggest that it is functionally distinct from that of localized tumors. Additionally, the large number of approved and trial agents used to treat metastatic RCC likely cause selective adaptations in the tumors. Circulating tumor DNA (ctDNA) is a platform to non-invasively determine the genomic profiles of these tumors. The objectives of the present study were to corroborate previous ctDNA studies in metastatic RCC, to identify novel mutations in metastatic RCC, and to compare ctDNA profiles obtained from plasma and urine in patients with metastatic RCC. ctDNA sequencing using the plasma and urine of 50 patients with metastatic RCC who received ctDNA profiling as part of routine clinical care at a single institution was performed using an investigational 120-gene panel. Genomic alterations (GAs) were identified in all 50 patients. The genes with the most GAs were GNAS, PTEN, MYC, MET and HNF1A and novel mutations in additional genes were identified. A significant correlation between the number of GAs detected in matched urine and plasma samples was also identified, but only 28.1% of GAs detected in plasma samples were also detected in matched urine samples. The results of the present study were consistent with those of the largest previous study of ctDNA from patients with metastatic RCC and may help identify additional potential targets for the treatment of such patients.
['Zhang|Jingbo|J|', 'Liu|Yunchao|Y|', 'Xu|Bing|B|', 'Li|Fuwei|F|', 'Wang|Yan|Y|', 'Li|Mengjian|M|', 'Du|Rong|R|', 'Zhou|Ye|Y|', 'Salgia|Meghan|M|', 'Yang|Lixin|L|', 'Jones|Jeremy O|JO|']
circulating tumor DNA renal cell carcinoma metastasis